These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 19262411)

  • 1. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
    Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
    Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Terheyden P; Becker JC; Kämpgen E; Bröcker EB
    Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
    Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    Becker JC; Terheyden P; Kämpgen E; Wagner S; Neumann C; Schadendorf D; Steinmann A; Wittenberg G; Lieb W; Bröcker EB
    Br J Cancer; 2002 Oct; 87(8):840-5. PubMed ID: 12373596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to the systemic treatment of melanoma.
    Chowdhury S; Vaughan MM; Gore ME
    Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
    Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
    Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
    Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.